EUROPE OPIOID INDUCED CONSTIPATION DRUG MARKET FORECAST 2017-2025
KEY FINDINGS
The Europe opioid constipation drug market is expected to grow at a CAGR of 4.00% during the forecast period of 2017-2025. The market value is predicted to increase from $896.3 million in 2016 and reach up to $1273.34 million by 2025.
MARKET INSIGHTS
The Europe opioid constipation drug market is mainly driven by the increasing opioids prescription in the region. The market can be segmented into two criteria. First is the market by drug type that includes drugs such as naloxegol, methyl naltrexone bromide, lubiprostone, others.of these, Lubiprostone is currently the most popular drug type in the region. The second market criteria is on the basis of the type of prescription that includes over the counter drugs and branded or generic prescribed drugs. The over the counter drugs are more popular as compared to the prescribed ones due to their ease of availability.
COMPETITIVE INSIGHTS
Some of the major companies in the market include:
The Europe opioid constipation drug market is expected to grow at a CAGR of 4.00% during the forecast period of 2017-2025. The market value is predicted to increase from $896.3 million in 2016 and reach up to $1273.34 million by 2025.
MARKET INSIGHTS
The Europe opioid constipation drug market is mainly driven by the increasing opioids prescription in the region. The market can be segmented into two criteria. First is the market by drug type that includes drugs such as naloxegol, methyl naltrexone bromide, lubiprostone, others.of these, Lubiprostone is currently the most popular drug type in the region. The second market criteria is on the basis of the type of prescription that includes over the counter drugs and branded or generic prescribed drugs. The over the counter drugs are more popular as compared to the prescribed ones due to their ease of availability.
COMPETITIVE INSIGHTS
Some of the major companies in the market include:
- Pfizer
- Daiichi Sankyo Co Ltd
- Progenics Pharmaceuticals Inc
- Nektar Therapeutics
- Allergan Plc
- Purdue Pharma L.P.
- Valeant Pharmaceuticals International
- Cosmo Pharmaceuticals Sa
- Daewoong Pharmaceutical Co., Ltd.
- Theravance Biopharma Inc
- C.B. Fleet Company, Inc.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
4. MARKET OVERVIEW
4.1. MARKET DEFINITION
4.2. KEY MARKET INSIGHTS
4.3. ATTRACTIVE INVESTMENT SCENARIO
4.4. POSITIONING OF KEY CIC DRUGS MANUFACTURERS IN THE MARKET
4.5. MARKET DRIVERS
4.5.1. RISING USE OF OPIOID
4.5.2. INCREASING GERIATRIC POPULATION
4.5.3. INCREASING OPIOIDS PRESCRIPTION IN EUROPE
4.5.4. EASY AVAILABILITY OF IMPROVED AND EFFECTIVE OIC DRUGS
4.6. RESTRAINTS
4.6.1. RESEARCH ON PAIN AND NEXT GENERATION ANALGESICS
4.6.2. SIDE EFFECTS OF OIC DRUGS
4.6.3. UNAWARENESS AND IGNORANCE AMONG PATIENTS
4.7. OPPORTUNITY
4.7.1. INCREASING USE OF OPIOIDS
4.8. CHALLENGES
4.8.1. LARGE NUMBER OF CONSIDERATIONS WHILE USING OPIOIDS
5. EUROPE OIC DRUG MARKET BY DRUG TYPE 2017-2025 ($ MILLION)
5.1. OVERVIEW
5.1.1. METHYL NALTREXONE BROMIDE
5.1.2. LUBIPROSTONE
5.1.3. NALOXEGOL
5.2. PIPELINE DRUG ANALYSIS: PHASE 3: NALDEMEDINE (YEAR OF LAUNCH TO 2022 $ MILLION)
5.3. PIPELINE DRUG ANALYSIS: PHASE 2: ALVIMOPAN, DOLCANATIDE (QUALITATIVE INFORMATION)
5.4. PIPELINE DRUG ANALYSIS: PHASE 3: ELOBIXIBAT (YEAR OF LAUNCH TO 2022 $ MILLION)
6. EUROPE CIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
6.1. PRESCRIBED DRUGS
6.1.1. BRANDED
6.1.2. GENERIC
6.2. OVER THE COUNTER DRUGS
7. KEY ANALYTICS
7.1. PORTERS FIVE FORCE MODEL
7.1.1. INTENSITY OF COMPETITIVE RIVALRYOMPETITION AMONG THE
7.1.2. BARGAINING POWER OF SUPPLIERS
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. THREAT OF SUBSTITUTE PRODUCTS
7.1.5. THREAT OF NEW ENTRANTS
7.2. VENDOR LANDSCAPE
7.3. OPPORTUNITY MATRIX
8. EUROPE OIC DRUGS MARKET BY COUNTRIES 2017-2025 ($ MILLION)
8.1. UK
8.2. GERMANY
8.3. REST OF THE EUROPE
9. COMPANY PROFILE
9.1. IRONWOOD PHARMACEUTICALS INC
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. STRATEGIC MOVES
9.1.4. SCOT ANALYSIS
9.2. DAIICHI SANKYO CO LTD
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. STRATEGIC MOVES
9.2.4. SCOT ANALYSIS
9.3. PFIZER
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. STRATEGIC MOVES
9.3.4. SCOT ANALYSIS
9.4. PROGENICS PHARMACEUTICALS INC
9.4.1. OVERVIEW
9.4.2. STRATEGIC MOVES
9.4.3. SCOT ANALYSIS
9.5. SHIONOGI & CO., LTD.
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. STRATEGIC MOVES
9.5.4. SCOT ANALYSIS
9.6. ALLERGAN PLC
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. STRATEGIC MOVES
9.6.4. SCOT ANALYSIS
9.7. NEKTAR THERAPEUTICS
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC MOVES
9.7.4. SCOT ANALYSIS
9.8. PURDUE PHARMA L.P.
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. STRATEGIC MOVES
9.8.4. SCOT ANALYSIS
9.9. S.L.A. PHARMA AG
9.9.1. OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. SCOT ANALYSIS
9.10. MUNDIPHARMA INTERNATIONAL LIMITED
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. STRATEGIC MOVES
9.10.4. SCOT ANALYSIS
9.11. ONO PHARMACEUTICAL CO., LTD.
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. STRATEGIC MOVES
9.11.4. SCOT ANALYSIS
9.12. TAKEDA PHARMACEUTICAL COMPANY LIMITED
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. STRATEGIC MOVES
9.12.4. SCOT ANALYSIS
9.13. THERAVANCE BIOPHARMA INC
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. STRATEGIC MOVES
9.13.4. SCOT ANALYSIS
9.14. VALEANT PHARMACEUTICALS INTERNATIONAL
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. STRATEGIC MOVES
9.14.4. SCOT ANALYSIS
9.15. COSMO PHARMACEUTICALS SA
9.15.1. OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. STRATEGIC MOVES
9.15.4. SCOT ANALYSIS
9.16. DAEWOONG PHARMACEUTICAL CO., LTD.
9.16.1. OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. STRATEGIC MOVES
9.16.4. SCOT ANALYSIS
9.17. C.B. FLEET COMPANY, INC.
9.17.1. OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. STRATEGIC MOVES
9.17.4. SCOT ANALYSIS
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
4. MARKET OVERVIEW
4.1. MARKET DEFINITION
4.2. KEY MARKET INSIGHTS
4.3. ATTRACTIVE INVESTMENT SCENARIO
4.4. POSITIONING OF KEY CIC DRUGS MANUFACTURERS IN THE MARKET
4.5. MARKET DRIVERS
4.5.1. RISING USE OF OPIOID
4.5.2. INCREASING GERIATRIC POPULATION
4.5.3. INCREASING OPIOIDS PRESCRIPTION IN EUROPE
4.5.4. EASY AVAILABILITY OF IMPROVED AND EFFECTIVE OIC DRUGS
4.6. RESTRAINTS
4.6.1. RESEARCH ON PAIN AND NEXT GENERATION ANALGESICS
4.6.2. SIDE EFFECTS OF OIC DRUGS
4.6.3. UNAWARENESS AND IGNORANCE AMONG PATIENTS
4.7. OPPORTUNITY
4.7.1. INCREASING USE OF OPIOIDS
4.8. CHALLENGES
4.8.1. LARGE NUMBER OF CONSIDERATIONS WHILE USING OPIOIDS
5. EUROPE OIC DRUG MARKET BY DRUG TYPE 2017-2025 ($ MILLION)
5.1. OVERVIEW
5.1.1. METHYL NALTREXONE BROMIDE
5.1.2. LUBIPROSTONE
5.1.3. NALOXEGOL
5.2. PIPELINE DRUG ANALYSIS: PHASE 3: NALDEMEDINE (YEAR OF LAUNCH TO 2022 $ MILLION)
5.3. PIPELINE DRUG ANALYSIS: PHASE 2: ALVIMOPAN, DOLCANATIDE (QUALITATIVE INFORMATION)
5.4. PIPELINE DRUG ANALYSIS: PHASE 3: ELOBIXIBAT (YEAR OF LAUNCH TO 2022 $ MILLION)
6. EUROPE CIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
6.1. PRESCRIBED DRUGS
6.1.1. BRANDED
6.1.2. GENERIC
6.2. OVER THE COUNTER DRUGS
7. KEY ANALYTICS
7.1. PORTERS FIVE FORCE MODEL
7.1.1. INTENSITY OF COMPETITIVE RIVALRYOMPETITION AMONG THE
7.1.2. BARGAINING POWER OF SUPPLIERS
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. THREAT OF SUBSTITUTE PRODUCTS
7.1.5. THREAT OF NEW ENTRANTS
7.2. VENDOR LANDSCAPE
7.3. OPPORTUNITY MATRIX
8. EUROPE OIC DRUGS MARKET BY COUNTRIES 2017-2025 ($ MILLION)
8.1. UK
8.2. GERMANY
8.3. REST OF THE EUROPE
9. COMPANY PROFILE
9.1. IRONWOOD PHARMACEUTICALS INC
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. STRATEGIC MOVES
9.1.4. SCOT ANALYSIS
9.2. DAIICHI SANKYO CO LTD
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. STRATEGIC MOVES
9.2.4. SCOT ANALYSIS
9.3. PFIZER
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. STRATEGIC MOVES
9.3.4. SCOT ANALYSIS
9.4. PROGENICS PHARMACEUTICALS INC
9.4.1. OVERVIEW
9.4.2. STRATEGIC MOVES
9.4.3. SCOT ANALYSIS
9.5. SHIONOGI & CO., LTD.
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. STRATEGIC MOVES
9.5.4. SCOT ANALYSIS
9.6. ALLERGAN PLC
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. STRATEGIC MOVES
9.6.4. SCOT ANALYSIS
9.7. NEKTAR THERAPEUTICS
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC MOVES
9.7.4. SCOT ANALYSIS
9.8. PURDUE PHARMA L.P.
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. STRATEGIC MOVES
9.8.4. SCOT ANALYSIS
9.9. S.L.A. PHARMA AG
9.9.1. OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. SCOT ANALYSIS
9.10. MUNDIPHARMA INTERNATIONAL LIMITED
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. STRATEGIC MOVES
9.10.4. SCOT ANALYSIS
9.11. ONO PHARMACEUTICAL CO., LTD.
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. STRATEGIC MOVES
9.11.4. SCOT ANALYSIS
9.12. TAKEDA PHARMACEUTICAL COMPANY LIMITED
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. STRATEGIC MOVES
9.12.4. SCOT ANALYSIS
9.13. THERAVANCE BIOPHARMA INC
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. STRATEGIC MOVES
9.13.4. SCOT ANALYSIS
9.14. VALEANT PHARMACEUTICALS INTERNATIONAL
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. STRATEGIC MOVES
9.14.4. SCOT ANALYSIS
9.15. COSMO PHARMACEUTICALS SA
9.15.1. OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. STRATEGIC MOVES
9.15.4. SCOT ANALYSIS
9.16. DAEWOONG PHARMACEUTICAL CO., LTD.
9.16.1. OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. STRATEGIC MOVES
9.16.4. SCOT ANALYSIS
9.17. C.B. FLEET COMPANY, INC.
9.17.1. OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. STRATEGIC MOVES
9.17.4. SCOT ANALYSIS
LIST OF TABLES
TABLE 1 EUROPE OIC DRUG MARKET BY COUNTRIES 2017-2025 ($ MILLION)
TABLE 2 PHARMACOLOGICAL APPROACHES TO TREAT OPIOID INDUCED CONSTIPATION
TABLE 3 LAXATIVES USED FOR OPIOID INDUCED CONSTIPATION
TABLE 4 SIDE EFFECTS OF USING LAXATIVES
TABLE 5 PATIENTS UNFIT FOR INTAKE OF OPIOIDS
TABLE 6 EUROPE OIC DRUG MARKET BY DRUG TYPE, 2017-2025 ($ MILLION)
TABLE 7 PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)
TABLE 8 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 9 PRODUCT PROFILE (NALOXEGOL)
TABLE 10 PIPELINE PRODUCT PROFILE (NALDEMEDINE)
TABLE 11 PIPELINE PRODUCT PROFILE (ALVIMOPAN, DOLCANATIDE)
TABLE 12 PIPELINE PRODUCT PROFILE (ELOBIXIBAT)
TABLE 13 EUROPE OIC DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 14 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 15 EUROPE PRESCRIBED OIC DRUGS MARKET 2017-2025($ MILLION)
TABLE 16 PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)
TABLE 17 PRODUCT PROFILE (METAMUCIL)
TABLE 18 PRODUCT PROFILE (BISACODYL)
TABLE 19 EUROPE OIC DRUG MARKET BY COUNTRIES 2017-2025 ($ MILLION)
TABLE 1 EUROPE OIC DRUG MARKET BY COUNTRIES 2017-2025 ($ MILLION)
TABLE 2 PHARMACOLOGICAL APPROACHES TO TREAT OPIOID INDUCED CONSTIPATION
TABLE 3 LAXATIVES USED FOR OPIOID INDUCED CONSTIPATION
TABLE 4 SIDE EFFECTS OF USING LAXATIVES
TABLE 5 PATIENTS UNFIT FOR INTAKE OF OPIOIDS
TABLE 6 EUROPE OIC DRUG MARKET BY DRUG TYPE, 2017-2025 ($ MILLION)
TABLE 7 PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)
TABLE 8 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 9 PRODUCT PROFILE (NALOXEGOL)
TABLE 10 PIPELINE PRODUCT PROFILE (NALDEMEDINE)
TABLE 11 PIPELINE PRODUCT PROFILE (ALVIMOPAN, DOLCANATIDE)
TABLE 12 PIPELINE PRODUCT PROFILE (ELOBIXIBAT)
TABLE 13 EUROPE OIC DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 14 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 15 EUROPE PRESCRIBED OIC DRUGS MARKET 2017-2025($ MILLION)
TABLE 16 PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)
TABLE 17 PRODUCT PROFILE (METAMUCIL)
TABLE 18 PRODUCT PROFILE (BISACODYL)
TABLE 19 EUROPE OIC DRUG MARKET BY COUNTRIES 2017-2025 ($ MILLION)
LIST OF FIGURES
FIGURE 1 EUROPE OIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 2 EUROPE OIC DRUG MARKET BY DRUG TYPE 2016 AND 2025 (%)
FIGURE 3 EUROPE OIC DRUG MARKET BY PRESCRIPTION TYPE 2016 (%)
FIGURE 4 INCREASING NUMBER OF OPIOID PRESCRIPTION ($ MILLION)
FIGURE 5 REASONS FOR THE GROWTH OF OPIOID MARKET.
FIGURE 6 COMMON SIDE EFFECTS OF MOVANTIK
FIGURE 7 MAJOR USAGE OF OPIOIDS
FIGURE 8 CONSIDERATIONS TAKEN WHILE THE OPIOID USAGE
FIGURE 9 EUROPE METHYL NALTREXONE BROMIDE OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 10 EUROPE LUBIPROSTONE OIC DRUG MARKET 2017-2025 ($MILLION)
FIGURE 11 EUROPE NALOXEGOL OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 12 EUROPE PRESCRIBED OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 13 EUROPE PRESCRIBED BRANDED OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 14 EUROPE PRESCRIBED GENERIC OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 15 EUROPE OVER THE COUNTER OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 16 EUROPE OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 17 UK OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 18 GERMANY OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 19 REST OF EUROPE OIC DRUG MARKET 2017-2025($ MILLION)
FIGURE 1 EUROPE OIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 2 EUROPE OIC DRUG MARKET BY DRUG TYPE 2016 AND 2025 (%)
FIGURE 3 EUROPE OIC DRUG MARKET BY PRESCRIPTION TYPE 2016 (%)
FIGURE 4 INCREASING NUMBER OF OPIOID PRESCRIPTION ($ MILLION)
FIGURE 5 REASONS FOR THE GROWTH OF OPIOID MARKET.
FIGURE 6 COMMON SIDE EFFECTS OF MOVANTIK
FIGURE 7 MAJOR USAGE OF OPIOIDS
FIGURE 8 CONSIDERATIONS TAKEN WHILE THE OPIOID USAGE
FIGURE 9 EUROPE METHYL NALTREXONE BROMIDE OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 10 EUROPE LUBIPROSTONE OIC DRUG MARKET 2017-2025 ($MILLION)
FIGURE 11 EUROPE NALOXEGOL OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 12 EUROPE PRESCRIBED OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 13 EUROPE PRESCRIBED BRANDED OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 14 EUROPE PRESCRIBED GENERIC OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 15 EUROPE OVER THE COUNTER OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 16 EUROPE OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 17 UK OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 18 GERMANY OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 19 REST OF EUROPE OIC DRUG MARKET 2017-2025($ MILLION)
